MVM announces partial sale of its holding in Ambio

MVM Partners LLP has partially divested its stake in Ambio Holdings, Inc. (“Ambio”) a global leader in peptide manufacturing and development to The Carlyle Group (“Carlyle”) (NASDAQ: CG). Equity for the transaction comes from Carlyle Asia Partners V, its flagship $6.55 billion Asia fund that makes buyout and strategic investments across a wide range of sectors in Asia Pacific. MVM remains a significant shareholder of Ambio and maintains representation on the company’s Board of Directors.

Dr. Eric Bednarski, Partner of MVM, said, “MVM was the first institutional investor in Ambio. Since our investment in November 2014, Ambio has increased revenue more than 350% and built a highly profitable business. We are pleased to add Carlyle as an institutional partner and will continue working with management to drive future success of the company.”

Ambio is a primary supplier of complex peptide active pharmaceutical ingredients to the global pharmaceutical industry and its customers include many of the largest branded, generic and biotechnology companies. Ambio also has a rich and growing pipeline of proprietary drug development programs for generic versions of the world’s best-selling peptide drugs. The company is headquartered in North Augusta, South Carolina, and has manufacturing operations in Shanghai, China.

Ambio Holdings, Inc.

Ambio Holdings, Inc.
Peptide pharmaceuticals

Downloads

DownloadPress Release

Latest News

Valneva initiates second Phase II study for its Lyme Disease vaccine candidate

Valneva has announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15

Valneva reports successful outcome of Phase 2 run-in for its Lyme disease vaccine candidate

Valneva SE has announced progress of its ongoing Phase 2 study for its leading, unique Lyme disease vaccine candidate, VLA15, into the main study phase

New data further validates Breast Cancer Index ability to predict extended endocrine therapy benefit

Biotheranostics, Inc. announces new pivotal data on the Breast Cancer Index that further validates its ability to accurately predict which women with early-stage, hormone receptor positive breast cancer will benefit from extended endocrine therapy

Valneva reports further positive results for its Chikungunya Vaccine Candidate

Phase I unblinded results up to month 7 showed an excellent immunogenicity and safety profile confirming Valneva's unique, single-shot vaccine candidate

Zipline selected as 2019 Red Herring Top 100 North America Winner

ZipLine Medical, Inc. was selected as a winner of the Red Herring Top 100 North America award, which recognizes the continent's most exciting and innovative private technology companies

MVM announces partial sale of its holding in Ambio

MVM Partners announces the partial sale of its holding in Ambio to The Carlyle Group